Plus Therapeutics Presents Positive Data from Ongoing ReSPECT Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases (GlobeNewswire) - Aug 13, 2022 - P1/2 | N=55| ReSPECT(NCT01906385) | Sponsor: Plus Therapeutics | "Dr. Brenner also presented a poster titled, Safety and Feasibility of Rhenium-186 NanoLiposome (186RNL) in Recurrent Glioma: the ReSPECT™ Phase 1 Trial [LOCL-08], which demonstrated that in 23 subjects with recurrent GBM receiving a single administration of 186RNL, significant overall survival benefits were observed in those achieving an average absorbed radiation dose greater than 100 Gy to the tumor compared to those with less absorption. These findings suggest a correlation in increasing convected drug volume and radiation dose with improvement in overall survival of patients and to date, 80% of patients in cohorts 5-7 met the threshold of high levels of absorption greater than 100 Gy."
P1 data • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor
|